Related Experiment Video
Updated: Jun 11, 2026
Protein Transfection of Mouse Lung
Published on: May 15, 2013
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and
Peter C Gøtzsche1, Helle Krogh Johansen
1The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, 3343, Copenhagen, Denmark, DK-2100.
Background:
Alpha-1 antitrypsin deficiency is an inherited disorder that can cause lung disease. People who smoke are more seriously affected and have a greater risk of dying from the disease.
Objectives:
To review the benefits and harms of augmentation therapy with alpha-1 antitrypsin in patients with alpha-1 antitrypsin deficiency and lung disease.
Search Strategy:
PubMed, the Cochrane Trials Register and ClinicalTrials.gov (7 January 2010), and the Cochrane Cystic Fibrosis & Genetic Disorders Group's Trials Register (13 March 2009).
Selection Criteria:
Randomised trials of augmentation therapy with alpha-1 antitrypsin compared with placebo or no treatment.
Data Collection And Analysis:
The two authors independently selected trials, extracted outcome data and assessed the risk of bias.
Main Results:
Two trials were included (total 140 patients) that ran for two to three years. All patients were ex- or never-smokers and had genetic variants that carried a very high risk of developing chronic obstructive pulmonary disease. Mortality data were not reported. There was no information on harms in the first trial; in the second trial, serious adverse events were reported to have occurred in 10 patients in the active group and in 18 patients in the placebo group. Annual number of exacerbations and quality of life were similar in the two groups; none of the trials reported on average number of lung infections or hospital admissions. Forced expiratory volume in one second deteriorated a little more in the active group than in the placebo group (difference was -20 ml per year; 95% confidence interval -41 to 1; p = 0.06). For carbon monoxide diffusion, the difference was -0.06 mmol/min/kPa per year (95% confidence interval -0.17 to 0.05; p = 0.31). Lung density measured by CT scan deteriorated a little less in the active group than in the placebo group (difference 1.14 g/l; 95% confidence interval 0.14 to 2.14; p = 0.03) over the total course of the trials.
Authors' Conclusions:
Augmentation therapy with alpha-1 antitrypsin cannot be recommended, in view of the lack of evidence of clinical benefit and the cost of treatment.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:29Venous Thrombosis III: Interprofessional Care
01:22Heart Failure VI: Adjunct Therapies
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...